ADCYTHERIX
Adcytherix is a biopharmaceutical firm that specializes in the development of new antibody drug conjugates (ADC) to treat diseases with a high unmet need, including cancer.
ADCYTHERIX
Social Links:
Industry:
Biotechnology Oncology
Founded:
2023-01-01
Address:
Marseille, Provence-Alpes-Cote D'Azur, France
Country:
France
Website Url:
http://www.adcytherix.com
Total Employee:
1+
Status:
Active
Total Funding:
30 M EUR
Current Advisors List
Current Employees Featured
Founder
Investors List
Dawn Biopharma
Dawn Biopharma investment in Seed Round - Adcytherix
Pureos Bioventures
Pureos Bioventures investment in Seed Round - Adcytherix
Pontifax
Pontifax investment in Seed Round - Adcytherix
RA Capital Management
RA Capital Management investment in Seed Round - Adcytherix
Official Site Inspections
http://www.adcytherix.com Semrush global rank: 11.29 M Semrush visits lastest month: 167
- Host name: unalocated.63.wixsite.com
- IP address: 185.230.63.186
- Location: Ashburn United States
- Latitude: 39.018
- Longitude: -77.539
- Metro Code: 511
- Timezone: America/New_York
- Postal: 20147
More informations about "Adcytherix"
Adcytherix - Crunchbase Company Profile & Funding
Jun 11, 2024 Organization. Adcytherix . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. About. ... Adcytherix focuses on developing novel antibody drug conjugates aimed at treating diseases with …See details»
Adcytherix Company Profile 2024: Valuation, Funding & Investors
Jun 11, 2024 Dawn Biopharma, Kinled Holding, Pontifax Venture Capital, Pureos Bioventures, and RA Capital Management are 5 of 6 investors who have invested in Adcytherix. Who are …See details»
Adcytherix - Products, Competitors, Financials, Employees, …
Jun 12, 2024 Adcytherix: Emergence team reunites for another ADC company. Jun 12, 2024. Adcytherix: Emergence team reunites for another ADC company French biotech to pursue …See details»
Adcytherix - LinkedIn
Adcytherix BV is a biotech company focused on the development of antibody drug conjugates for high unmet need diseases such as cancer.See details»
Adcytherix - Funding, Financials, Valuation & Investors - Crunchbase
Jun 11, 2024 Adcytherix is a biopharmaceutical firm that specializes in the development of new antibody drug conjugates (ADC). Search Crunchbase. Start Free Trial . Chrome Extension. ...See details»
Adcytherix - Contacts, Employees, Board Members, Advisors
Organization. Adcytherix . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Highlights. Employee Profiles 2. Number of Board Member and Advisor …See details»
Adcytherix - VentureRadar
Adcytherix is a biopharmaceutical company dedicated to developing innovative antibody drug conjugates (ADC) aimed at treating diseases with high unmet medical needs, such as cancer. …See details»
ADCYTHERIX - Societe.com
ADCYTHERIX, société par actions simplifiée, au capital social de 475,39 EURO, dont le siège social est situé au 17 BOULEVARD AUGUSTIN CIEUSSA, 13007 MARSEILLE, immatriculée …See details»
Adcytherix - Company Profile - Tracxn
Jun 11, 2024 Competitive landscape of Adcytherix Adcytherix ranks 156th among 509 competitors which include BeiGene, Moderna and Ultragenyx. 157 of its competitors are …See details»
Adcytherix Launches with € 30m in Seed Funding to …
Jun 11, 2024 Adcytherix SAS announced its incorporation and seed funding of € 30 million to develop novel antibody-drug- conjugates (ADCs) for the treatment of high unmet need diseases such as cancer. The company was founded by …See details»
Adcytherix - Raised $32.3M Funding from 3 investors - Tracxn
Jun 11, 2024 Adcytherix has raised a total funding of $32.3M over 1 round from 3 investors. Investors include RA Capital Management, Pontifax and 1 other. Their latest funding round …See details»
Adcytherix Launches with € 30m in Seed Funding to Develop
Jun 11, 2024 Adcytherix Launches with € 30m in Seed Funding to Develop Next Generation Antibody Drug Conjugates Vision is to establish a leading ADC developer to treat high unmet …See details»
Adcytherix launches with seed funding for ADC development
Jun 11, 2024 France-based biopharmaceutical company Adcytherix has announced its launch with seed funding of €30m ($32.2m) aimed at developing new antibody-drug conjugates …See details»
Adcytherix Launches and Raises 30 Million Euros in Seed Funding …
Adcytherix is a biopharmaceutical company focused on developing novel antibody-drug conjugates (ADCs) to treat diseases with unmet need, such as cancer. The company is led by …See details»
Adcytherix Launches with € 30m in Seed Funding to Develop Next ...
Marseille, France, 11 June 2024: Adcytherix SAS today announced its incorporation and seed funding of € 30 million to develop novel antibody-drug- conjugates (ADCs) for the treatment of …See details»
Adcytherix Launches with €30 Million Seed Funding to Pioneer …
Jun 11, 2024 Adcytherix SAS announced its incorporation and seed funding of € 30 million to develop novel antibody-drug- conjugates (ADCs) for the treatment of high unmet need …See details»
ADCX-020 - Drug Targets, Indications, Patents - Synapse
ADCX-020, Initially developed by Adcytherix, Now, its global highest R&D status is Preclinical, Therapeutic Areas: Neoplasms, Active Indication: Neoplasms, Active Org.: Adcytherix. ...See details»
Adcytherix Launches with € 30m in Seed Funding to Develop Next ...
Jun 10, 2024 Vision is to establish a leading ADC developer to treat high unmet need diseases such as cancer.Founded by the team that founded and sold Emergence Therapeutics to Eli …See details»
Adcytherix aims for innovation as startup in crowded ADC space
Jun 11, 2024 Fresh from the sale of one antibody-drug conjugate (ADC) company, Jack Elands has formed another, raising €30 million (US$32.2 million) in seed funding for Adcytherix SAS. …See details»
Granville Crossbody Bag - Arc'teryx
The minimalist design’s efficient organization includes a secure internal pocket for your smartphone and keys, the AeroForm back panel allows airflow, and the removable strap gives …See details»